Pediatric Exclusivity and Rare Pediatric Disease Priority Review
Pediatric Exclusivity and Rare Pediatric Disease Priority Review How Pediatric Exclusivity and Priority Review Vouchers Accelerate Rare Disease Drug Development Why Pediatric Incentives Are Critical in Rare Disease Drug Development Over 50% of rare diseases affect children, yet pediatric drug development often lags due to ethical complexities, limited commercial return, and small patient populations. To…
Read More “Pediatric Exclusivity and Rare Pediatric Disease Priority Review” »